REBECCA Real-world Early BrEast CanCer mAnagement

REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06856343

Acronym

REBECCA

Enrollment

126

Registered

2025-03-04

Start date

2024-12-30

Completion date

2028-01-31

Last updated

2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.

Detailed description

The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female aged ≥ 18 years * Patient diagnosed with HER2-negative eBC * Patient about to be initiated with adjuvant Olaparib at their physician's discretion * Patient has been informed and does not object to participation in the study.

Exclusion criteria

* Patient not consenting to participate. * Patients included in the Early Access Program

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients who receive Olaparib for the full treatment duration	18 months after inclusion	The primary outcome is the evaluation of the proportion of patients who receive Olaparib for the full treatment duration, described as 12 months of treatment.

Secondary

Measure	Time frame	Description
BRCA characteristics: Mutation type	18 months after inclusion	Regarding BRCA characteristics: Mutation type: Tumoral (if only tumoral testing performed), somatic, germline.
Type of variants	18 months after inclusion	Type of variants: BRCA1 and/or BRCA2, PALB2 mutation, presence of other HRR gene mutations, presence of other mutations
Medical history	18 months after inclusion	Family and personal history of cancer/type
Time to Olaparib treatment discontinuation	18 months after inclusion	Time to Olaparib Treatment Discontinuation (TTD) or death

Countries

France

Contacts

CONTACTAstraZeneca Clinical Study Information Center

information.center@astrazeneca.com1-877-240-9479

Outcome results